Why is Concord Biotech falling/rising?

As of 15-Sep, Concord Biotech Ltd's stock price is currently at 1,658.00, reflecting an increase of 21.0 points or 1.28%. The stock has shown a positive performance today, outperforming its sector by 1.73% and achieving a consecutive gain over the last two days with a total return of 1.34%. Despite this short-term uptick, the company has faced challenges, including a significant drop in PAT for the latest quarter, which fell by 52.6% compared to the previous four-quarter average, and the lowest net sales recorded at Rs 203.99 crore. Additionally, while the company boasts a high return on equity (ROE) of 19.76% and a low debt-to-equity ratio, it is trading at a premium compared to its peers, which raises concerns about its valuation given the poor long-term growth prospects.
In the broader market context, Concord Biotech's short-term return of 2.78% over the past week exceeds the Sensex's return of 1.24%. However, the stock has underperformed significantly on a year-to-date basis, with a decline of 24.98% compared to the Sensex's gain of 4.67%. The recent rise in stock price may be attributed to increased investor participation, as evidenced by a 106.06% increase in delivery volume, but the overall sentiment remains cautious due to falling institutional investment and the company's underwhelming long-term performance.